| General Information of This Metabolic Reaction (MR) (ID:
MR002088) |
| Formula |
|
| Reactant |
R-95913 |
Product |
R-138727 |
|
Reactant Info
|
Product Info
|
|
Metabolic Enzyme
|
Cytochrome P450 2B6 (CYP2B6)
|
DME Info
|
|
Cytochrome P450 3A4 (CYP3A4)
|
DME Info
|
|
Cytochrome P450 2C9 (CYP2C9)
|
DME Info
|
|
Mephenytoin 4-hydroxylase (CYP2C19)
|
DME Info
|
|
|
|
|
|
|
|
| Other MR(s) Related to The Reactant of This MR |
|
Other MR(s) That Produce The Reactant of This MR
|
|
|
| Other MR(s) Related to The Product of This MR |
|
Other MR(s) That Metabolize The Produtc of This MR
|
|
|
| References |
| 1 |
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
|
| 2 |
Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectrom. 2007;21(2):169-79. doi: 10.1002/rcm.2813.
|
| 3 |
Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Prasugrel in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2023 Jan;12(1):21-29. doi: 10.1002/cpdd.1172.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.